ANALYSIS OF DRUG INTERACTIONS BETWEEN GLP-1 RECEPTOR AGONISTS AND MEDICATIONS USED IN THE TREATMENT OF CARDIOMETABOLIC DISEASES
DOI:
https://doi.org/10.51891/rease.v12i11.32920Keywords:
Drug interactions, GLP-1 receptor agonists, Cardiometabolic diseasesAbstract
Drug interactions involving glucagon-like peptide-1 (GLP-1) receptor agonists and medications used to treat cardiometabolic diseases deserve attention due to their potential effects on pharmacotherapy safety. Accordingly, this study aimed to analyze these interactions through a documentary, descriptive study with a qualitative approach, based on information available on the Drugs.com platform. Interactions involving semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, and tirzepatide were analyzed in combination with medications used to treat diabetes mellitus, hypertension, and dyslipidemia. The results showed that the identified interactions were mainly related to glycemic control and renal function. The main findings included the risk of hypoglycemia when these drugs are combined with certain antidiabetic agents and the possibility of renal alterations in some combinations, particularly those involving exenatide. These findings highlight the importance of identifying potential drug interactions to promote the safe use of these treatments and help prevent complications. It is concluded that pharmacotherapeutic monitoring is essential for assessing the risks associated with drug combinations and supporting safer treatment tailored to each patient's needs.
Downloads
Downloads
Published
Issue
Section
Categories
License
Atribuição CC BY